Compare SOLAI Limited (SLAI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SOLAI Limited vs Sanofi SA — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 6281× SOLAI Limited's market cap, and Sanofi SA pays a 5.5% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| SLAI | SNY | |
|---|---|---|
Market Cap | $16.69M | $104.83B |
Sector | Technology | Health |
52-Week High | $26.74 | $52.34 |
52-Week Low | $2.74 | $41.33 |
Enterprise Value | $16.33M | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement, while facing NYSE delisting proceedings announced July 16, 2026. The company shows severe financial distress with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Recent developments include a 7:1 reverse stock split effective June 2026 and acquisition of a 51% stake in NEURALAND. Technical indicators show mixed signals with an overall bullish trend but overbought RSI conditions.
The outlook remains highly speculative given delisting risks and persistent losses. Investment opportunity exists only for speculative traders betting on turnaround potential from recent acquisitions and AI product launches. Primary risks include imminent delisting, negative cash flow, and unsustainable financial performance that threatens ongoing operations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
